Takeda Pharmaceutical Faces Landmark RICO Class Action Over Actos Cancer Risk Allegations
- The Ninth Circuit upheld a class certification order in a RICO lawsuit against Takeda over Actos' cancer risks.
- Takeda and Eli Lilly allegedly concealed bladder cancer risks linked to Actos, raising ethical concerns about patient safety.
- The lawsuit could lead to over $7 billion in damages and set a precedent for pharmaceutical accountability and transparency.
Legal Landmark for Takeda: RICO Class Action Advances
The U.S. Court of Appeals for the Ninth Circuit has recently upheld a pivotal class certification order in the ongoing case of Painters & Allied Trades District Council 82 Health Care Fund v. Takeda Pharmaceutical Company Limited. This ruling marks a significant development in a national RICO class action lawsuit, which is the first of its kind against a major pharmaceutical company. The case alleges that Takeda, alongside Eli Lilly, conspired to conceal the bladder cancer risks associated with their diabetes medication, Actos (pioglitazone). The court’s decision allows a national class of third-party payers to pursue damages that could exceed $7 billion, highlighting the potential financial repercussions for the pharmaceutical giants.
The lawsuit, now in its eleventh year, draws on internal documents suggesting that both Takeda and Eli Lilly were aware of the cancer risks linked to Actos as early as 1999. This knowledge raises serious ethical questions about corporate responsibility and patient safety. Following a 2011 mandate from the FDA requiring labeling changes to warn of bladder cancer risks, sales of Actos plummeted by 80%. This dramatic decline underscores the impact of the alleged deceptive practices, which have left millions of diabetic patients uninformed about their exposure to potential carcinogens. Legal experts indicate that the case serves as a testament to a legacy of fraud within the pharmaceutical industry, prompting calls for greater accountability.
R. Brent Wisner, managing partner at Wisner Baum LLP and national class counsel for the plaintiffs, expresses eagerness to move forward to trial, emphasizing the strong evidence of deception that led to billions of dollars in fraudulent sales of Actos. The Ninth Circuit's affirmation of the class certification not only advances the case toward trial but also establishes a crucial legal precedent under the RICO Act. This ruling signals a potential shift in how pharmaceutical companies are held liable for their actions, particularly regarding transparency and patient safety, enhancing the scrutiny of corporate practices in the industry.
In related news, this case may encourage other entities to pursue similar legal actions against pharmaceutical companies, particularly as the public grows increasingly aware of the risks associated with certain medications. The outcome of this trial could set important boundaries for pharmaceutical marketing practices and the extent to which companies must disclose risks to consumers and healthcare providers alike. As the case progresses, it could become a landmark moment in the accountability of pharmaceutical companies within the U.S. legal framework.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…

